Trial · NCT00973102
Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)
NCT00973102, Phase 2, Completed, University of Texas Southwestern Medical Center; results first posted 2020-03-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock). Trials, record NCT00973102. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00973102
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)
- NCT number
- NCT00973102
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 50 participants, actual
- Lead sponsor
- University of Texas Southwestern Medical Center
- Conditions
- Hemorrhagic Shock
- Interventions
- Premarin IV, Placebo
- First posted
- 2009-09-09
- Last updated
- 2020-03-19
- Results first posted
- 2020-03-19
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Survival | 28 Days | Survival is defined as the number of patients who were discharged from the hospital alive prior to 28 days post injury or the number of patients still alive in the hospital 28 days post injury. The trial examines the rate of enrolled patients on each arm who survived to 28 days. |
| Secondary | Acute Respiratory Distress Syndrome (ARDS) Free Survival | 28 days | ARDS is a life-threatening condition characterized by inflammation of the lungs. The trial measures the number of days alive and without ARDS within 28 days post injury. Patients who die within 28 days are given value of 0, similarly, patients who live 28 days but have ARDS for all 28 days. A higher score (greater days) indicates better prognosis. Exudative stage is 0-6 days, proliferative stage is 7-10 days, Fibrotic stage is \>10-14 days. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Survival | 28 Days | participants | NUMBER | |
| SECONDARY | Acute Respiratory Distress Syndrome (ARDS) Free Survival | 28 days | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Survival | Premarin IV | 16 | participants | ||
| Survival | Placebo | 21 | participants | ||
| Acute Respiratory Distress Syndrome (ARDS) Free Survival | Premarin IV | 3.00 | Standard Deviation 3.46 | units on a scale | |
| Acute Respiratory Distress Syndrome (ARDS) Free Survival | Placebo | 3.33 | Standard Deviation 3.01 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Premarin IV | 24 | |
| Overall Study | STARTED | Placebo | 26 | |
| Overall Study | COMPLETED | Premarin IV | 23 | |
| Overall Study | COMPLETED | Placebo | 25 | |
| Overall Study | NOT COMPLETED | Premarin IV | 1 | |
| Overall Study | NOT COMPLETED | Placebo | 1 |
Source ClinicalTrials.gov
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Pneumonia | Infections and infestations | Premarin IV | 0 | 23 | 0 |
| serious | Pneumonia | Infections and infestations | Placebo | 1 | 25 | 1 |
| serious | Bloodstream | Infections and infestations | Premarin IV | 1 | 23 | 1 |
| serious | Bloodstream | Infections and infestations | Placebo | 0 | 25 | 0 |
| serious | Urinary tract infection | Infections and infestations | Premarin IV | 1 | 23 | 1 |
| serious | Urinary tract infection | Infections and infestations | Placebo | 1 | 25 | 1 |
| serious | Line infection | Infections and infestations | Premarin IV | 0 | 23 | 0 |
| serious | Line infection | Infections and infestations | Placebo | 1 | 25 | 1 |
| serious | Wound infection | Infections and infestations | Premarin IV | 2 | 23 | 2 |
| serious | Wound infection | Infections and infestations | Placebo | 4 | 25 | 4 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Premarin IV | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Premarin IV | 0 | 23 |
| Total, other adverse events | Placebo | 0 | 25 |
| Total, serious adverse events | Premarin IV | 5 | 23 |
| Total, serious adverse events | Placebo | 7 | 25 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Premarin IV vs Placebo: Survival | Trial comparisons |
| Premarin IV vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00973102
GET https://conductscience.org/api/trials/v1/NCT00973102/registered